Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | FGFR1 |
Variant | A121D |
Impact List | missense |
Protein Effect | no effect - predicted |
Gene Variant Descriptions | FGFR1 A121D lies within the extracellular domain of the Fgfr1 protein (UniProt.org). A121D results in transformation activity similar to wild-type Fgfr1 in cultured cells (PMID: 34272467), and therefore, is predicted to have no effect on Fgfr1 protein function. |
Associated Drug Resistance | |
Category Variants Paths |
FGFR1 mutant FGFR1 A121D |
Transcript | NM_023110.3 |
gDNA | chr8:g.38428432G>T |
cDNA | c.362C>A |
Protein | p.A121D |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_001354367.1 | chr8:g.38428432G>T | c.362C>A | p.A121D | RefSeq | GRCh38/hg38 |
XM_006716304.2 | chr8:g.38428432G>T | c.362C>A | p.A121D | RefSeq | GRCh38/hg38 |
XM_006716303.4 | chr8:g.38428432G>T | c.362C>A | p.A121D | RefSeq | GRCh38/hg38 |
NM_023110.3 | chr8:g.38428432G>T | c.362C>A | p.A121D | RefSeq | GRCh38/hg38 |
NM_001174065.1 | chr8:g.38428432G>T | c.362C>A | p.A121D | RefSeq | GRCh38/hg38 |
NM_015850.3 | chr8:g.38428432G>T | c.362C>A | p.A121D | RefSeq | GRCh38/hg38 |
XM_017013222.2 | chr8:g.38428432G>T | c.362C>A | p.A121D | RefSeq | GRCh38/hg38 |
XM_017013221.1 | chr8:g.38428432G>T | c.362C>A | p.A121D | RefSeq | GRCh38/hg38 |
XM_017013224.2 | chr8:g.38428432G>T | c.362C>A | p.A121D | RefSeq | GRCh38/hg38 |
NM_001354369.2 | chr8:g.38428432G>T | c.362C>A | p.A121D | RefSeq | GRCh38/hg38 |
XM_017013225.3 | chr8:g.38428432G>T | c.362C>A | p.A121D | RefSeq | GRCh38/hg38 |
XM_006716303.3 | chr8:g.38428432G>T | c.362C>A | p.A121D | RefSeq | GRCh38/hg38 |
NM_001174063.1 | chr8:g.38428432G>T | c.362C>A | p.A121D | RefSeq | GRCh38/hg38 |
NM_001354367.2 | chr8:g.38428432G>T | c.362C>A | p.A121D | RefSeq | GRCh38/hg38 |
XM_006716307.2 | chr8:g.38428432G>T | c.362C>A | p.A121D | RefSeq | GRCh38/hg38 |
XM_047421569.1 | chr8:g.38428432G>T | c.362C>A | p.A121D | RefSeq | GRCh38/hg38 |
XM_017013221.2 | chr8:g.38428432G>T | c.362C>A | p.A121D | RefSeq | GRCh38/hg38 |
NM_001410922.1 | chr8:g.38428432G>T | c.362C>A | p.A121D | RefSeq | GRCh38/hg38 |
NM_001354369.1 | chr8:g.38428432G>T | c.362C>A | p.A121D | RefSeq | GRCh38/hg38 |
NM_023110.2 | chr8:g.38428432G>T | c.362C>A | p.A121D | RefSeq | GRCh38/hg38 |
XM_006716307.1 | chr8:g.38428432G>T | c.362C>A | p.A121D | RefSeq | GRCh38/hg38 |
NM_001174063.2 | chr8:g.38428432G>T | c.362C>A | p.A121D | RefSeq | GRCh38/hg38 |
NM_015850.4 | chr8:g.38428432G>T | c.362C>A | p.A121D | RefSeq | GRCh38/hg38 |
NM_001174065.2 | chr8:g.38428432G>T | c.362C>A | p.A121D | RefSeq | GRCh38/hg38 |
XM_047421570.1 | chr8:g.38428432G>T | c.362C>A | p.A121D | RefSeq | GRCh38/hg38 |
XM_006716304.1 | chr8:g.38428432G>T | c.362C>A | p.A121D | RefSeq | GRCh38/hg38 |
XM_017013225.2 | chr8:g.38428432G>T | c.362C>A | p.A121D | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR1 A121D | Advanced Solid Tumor | predicted - sensitive | Fexagratinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR1 A121D were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |
FGFR1 A121D | Advanced Solid Tumor | predicted - sensitive | Infigratinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR1 A121D were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |
FGFR1 A121D | Advanced Solid Tumor | predicted - resistant | Dovitinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR1 A121D were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467). | 34272467 |
FGFR1 A121D | Advanced Solid Tumor | predicted - sensitive | Erdafitinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR1 A121D were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |
FGFR1 A121D | Advanced Solid Tumor | predicted - sensitive | Futibatinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR1 A121D were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |
FGFR1 A121D | Advanced Solid Tumor | predicted - sensitive | Pemigatinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR1 A121D were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |
FGFR1 A121D | Advanced Solid Tumor | predicted - sensitive | E7090 | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR1 A121D were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |